Literature DB >> 12796399

The role of novel oncogenes squamous cell carcinoma-related oncogene and phosphatidylinositol 3-kinase p110alpha in squamous cell carcinoma of the oral tongue.

Cherry L Estilo1, Pornchai O-Charoenrat, Ivan Ngai, Snehal G Patel, Pabbathi G Reddy, Su Dao, Ashok R Shaha, Dennis H Kraus, Jay O Boyle, Richard J Wong, David G Pfister, Joseph M Huryn, Ian M Zlotolow, Jatin P Shah, Bhuvanesh Singh.   

Abstract

PURPOSE: Amplification at chromosome 3q26.3 is a common and crucial event in head and neck squamous cell carcinoma (HNSCC), impacting significantly on tumor progression and clinical outcome. Two novel oncogenes, namely squamous cell carcinoma (SCC)-related oncogene (SCCRO) and PIK3CA (gene encoding phosphatidylinositol-3 kinase catalytic alpha-polypeptide), have been identified as targets of 3q26.3 amplification. This study aimed to delineate the role of SCCRO and PIK3CA in the pathogenesis of oral tongue SCC. EXPERIMENTAL
DESIGN: The association between gene copy number for SCCRO and PIK3CA measured by fluorescence in situ hybridization and level of mRNA expression quantitated by real-time reverse transcription-PCR was assessed in a panel of human HNSCC cell lines. In addition, gene expression in 49 consecutive primary SCCs of the oral tongue was determined and correlated with clinicopathological characteristics and outcome.
RESULTS: The mRNA level of SCCRO and PIK3CA was significantly correlated to the gene copy number in nine HNSCC cell lines. In addition, the expression level of SCCRO and PIK3CA was significantly greater in malignant tissues compared with those in histologically normal mucosae (2.17- and 2.46-fold, respectively; P < 0.001). Matched tumor normal control analysis revealed that 24.5 and 69.4% of patients expressed high levels of SCCRO and PIK3CA, respectively. Univariate analyses demonstrated that SCCRO overexpression correlated with nodal metastases (P = 0.05) and advanced stage (P = 0.02), whereas PIK3CA overexpression was associated with vascular invasion (P = 0.04). Only SCCRO overexpression was associated with disease-specific (P = 0.04) and overall survival (P = 0.02). Furthermore, SCCRO overexpression remained an independent predictor for cervical nodal metastasis on multivariate regression analysis (chi(2) likelihood ratio = 4.38; P = 0.04).
CONCLUSIONS: Although both SCCRO and PIK3CA may play a role in the pathogenesis of oral tongue SCC through amplification at 3q26, SCCRO appears to be a significant predictor of regional metastasis and may be a marker for tumor aggressiveness and clinical outcome.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12796399

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  30 in total

1.  PIK3CA polymorphisms associated with susceptibility to hepatocellular carcinoma.

Authors:  Hong-Guang Li; Fang-Feng Liu; Hua-Qiang Zhu; Xu Zhou; Jun Lu; Hong Chang; Jin-Hua Hu
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

2.  Chromosomal changes characterize head and neck cancer with poor prognosis.

Authors:  Verena L Bauer; Herbert Braselmann; Michael Henke; Dominik Mattern; Axel Walch; Kristian Unger; Michael Baudis; Silke Lassmann; Reinhard Huber; Johannes Wienberg; Martin Werner; Horst F Zitzelsberger
Journal:  J Mol Med (Berl)       Date:  2008-09-23       Impact factor: 4.599

3.  The determinants of head and neck cancer: Unmasking the PI3K pathway mutations.

Authors:  Fernanda S Giudice; Cristiane H Squarize
Journal:  J Carcinog Mutagen       Date:  2013-08-02

4.  SCCRO3 (DCUN1D3) antagonizes the neddylation and oncogenic activity of SCCRO (DCUN1D1).

Authors:  Guochang Huang; Cameron Stock; Claire C Bommeljé; Víola B Weeda; Kushyup Shah; Sarina Bains; Elizabeth Buss; Manish Shaha; Willi Rechler; Suresh Y Ramanathan; Bhuvanesh Singh
Journal:  J Biol Chem       Date:  2014-10-27       Impact factor: 5.157

5.  Genomic characterization of gene copy-number aberrations in endometrial carcinoma cell lines derived from endometrioid-type endometrial adenocarcinoma.

Authors:  Yingmei Wang; Da Yang; David Cogdell; Limei Hu; Fengxia Xue; Russell Broaddus; Wei Zhang
Journal:  Technol Cancer Res Treat       Date:  2010-04

6.  Mutational analyses of the BRAF, KRAS, and PIK3CA genes in oral squamous cell carcinoma.

Authors:  Karl C Bruckman; Frank Schönleben; Wanglong Qiu; Victoria L Woo; Gloria H Su
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2010-09-01

7.  Piperidinyl Ureas Chemically Control Defective in Cullin Neddylation 1 (DCN1)-Mediated Cullin Neddylation.

Authors:  Jared T Hammill; Daniel C Scott; Jaeki Min; Michele C Connelly; Gloria Holbrook; Fangyi Zhu; Amy Matheny; Lei Yang; Bhuvanesh Singh; Brenda A Schulman; R Kiplin Guy
Journal:  J Med Chem       Date:  2018-03-26       Impact factor: 7.446

8.  Discovery of an Orally Bioavailable Inhibitor of Defective in Cullin Neddylation 1 (DCN1)-Mediated Cullin Neddylation.

Authors:  Jared T Hammill; Deepak Bhasin; Daniel C Scott; Jaeki Min; Yizhe Chen; Yan Lu; Lei Yang; Ho Shin Kim; Michele C Connelly; Courtney Hammill; Gloria Holbrook; Cynthia Jeffries; Bhuvanesh Singh; Brenda A Schulman; R Kiplin Guy
Journal:  J Med Chem       Date:  2018-03-26       Impact factor: 7.446

9.  PIK3CA mutations in head and neck squamous cell carcinoma.

Authors:  Wanglong Qiu; Frank Schönleben; Xiaojun Li; Daniel J Ho; Lanny G Close; Spiros Manolidis; Boyce P Bennett; Gloria H Su
Journal:  Clin Cancer Res       Date:  2006-03-01       Impact factor: 12.531

10.  The dual pathway inhibitor rigosertib is effective in direct patient tumor xenografts of head and neck squamous cell carcinomas.

Authors:  Ryan T Anderson; Stephen B Keysar; Daniel W Bowles; Magdalena J Glogowska; David P Astling; J Jason Morton; Phuong Le; Adrian Umpierrez; Justin Eagles-Soukup; Gregory N Gan; Brian W Vogler; Daniel Sehrt; Sarah M Takimoto; Dara L Aisner; Francois Wilhelm; Barbara A Frederick; Marileila Varella-Garcia; Aik-Choon Tan; Antonio Jimeno
Journal:  Mol Cancer Ther       Date:  2013-07-19       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.